High doses of dextromethorphan (20-42 mglkglday) were given to four critically ill children with seizures and frequent epileptiform abnormalities in the EEG that were refractory to antiepileptic drugs. Their acute diseases (hypoxia, head trauma and hypoxia, neurodegenerative disease, hypoglycaemia) were thought to be due in part to N-methyl-Daspartate (NAIDA) receptor mediated processes.
Abstract
High doses of dextromethorphan (20-42 mglkglday) were given to four critically ill children with seizures and frequent epileptiform abnormalities in the EEG that were refractory to antiepileptic drugs. Their acute diseases (hypoxia, head trauma and hypoxia, neurodegenerative disease, hypoglycaemia) were thought to be due in part to N-methyl-Daspartate (NAIDA) receptor mediated processes.
Treatment with dextromethorphan, an NMDA receptor antagonist, was started between 48 hours and 14 days after the critical incident. In three patients the EEG improved considerably within 48 hours and seizures ceased within 72 hours. In the patient with neurodegenerative disease the effect on the EEG was impressive, but the seizures were not controlled. Despite the improvement of the EEG the clinical outcome was poor in all children: three died in the critical period or due to the progressing disease; the patient with hypoglycaemia survived with severe neurological sequelae. Plasma concentrations of dextromethorphan varied between 74-1730 ng/ml and its metabolite dextrorphan varied between 349-3790 nglml. In one patient corresponding concentrations in CSF were lower than those in plasma. The suppression of epileptic discharges by the doses of dextromethorphan given suggests that such doses are sufficient to block NMDA receptors. (7 Neurol Neurosurg Psychiatry 1994; 57:333-339) Dextromethorphan, a morphine derivative without affinity for opioid receptors, has been used as an antitussive for more than 30 years. Recently, the drug was shown to have anticonvulsant properties in several in vitro1-3 and in vivo models of epilepsy.4A6
Dextromethorphan is a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor 3a) . A barbiturate coma with electrocerebral silence for 24 hours had no effect; therefore dextromethorphan was added (35 mg/kg/ day). After discontinuation of pentobarbitone the continuous right hemiconvulsions relapsed, occasionally coinciding with contracortical spike wave complexes (fig 3b) . SEP amplitudes were attenuated in both The underlying mechanism is believed to be a block of the NMDA receptor channel. This is also assumed for the main metabolite of dextromethorphan, dextrorphan.7-9 Overstimulation of the NMDA receptor seems to play a key part in brain damage in hypoxia (cases 1 and 2), severe head trauma (case 2), hypoglycaemia (case 4), and neurodegenerative diseases (case 3).2>23 Epilepsy in these patients may be induced by NMDA receptormediated processes. In animal studies of NMDA-induced convulsions, only NMDA receptor antagonists, and not conventional antiepileptic drugs, are effective.5 In seizures caused by other pathomechanisms, the NMDA receptor antagonists prevent epileptic brain damage even when they do not suppress electrographic seizures.2425
The additional effect of dextromethorphan on voltage-gated calcium channels might also contribute to the anticonvulsant properties. Blocking calcium currents has been shown to have an anticonvulsant effect in in vitro26 and in vivo experiments.27 Much higher concentrations of dextromethorphan are necessary to inhibit the voltage-gated calcium channels than to block NMDA-induced currents. 9 Clinical experiences with dextromethorphan were reported by Fisher et al.28 They gave dextromethorphan (120 mg/day 2 mg/kg/day) as add-on therapy to adults with intractable complex partial seizures, without Figure 4 Case 4, after severe hypoglycaemia (A) 5th day, drug refractory multifocal slow spike wave complexes; (B) 48 hours after addition of dextromethorphan (35 mglkglday) to treatment metabolites might be different. Dextromethorphan, for example, seems to be nearly 10 times more potent in blocking NMDAinduced currents than dextromethorphan.9 The metabolism of dextromethorphan to dextrorphan or other compounds varies between patients32 and may be influenced by other drugs.
CLINICAL OUTCOME The clinical outcome of our patients was disappointing. According to the post mortem examination in case 1, the initial EEG pattern in case 2, the clinical course of the brother in case 3, and the severe hypoglycaemia with long lasting refractory status epilepticus in case 4, no other outcome could be expected. Treatment with dextromethorphan was started several (2-14) days after the initial event-that is, probably too late to prevent NMDA-induced excitotoxicity.
The lack of effect on some convulsions was also disappointing. By contrast with our first case,14 myoclonic jerks in case 3 were unaffected by dextromethorphan, although contracortical spike wave complexes in the EEG disappeared. A side effect of dextromethorphan'9 could be excluded, because the myoclonic jerks occurred even before dextromethorphan was added. Although sharp and spike wave complexes had disappeared in case 4, tonic seizures and trismus persisted for several days. SIDE 
EFFECTS
Dextromethorphan is an over the counter antitussive drug with a wide margin of safety and rare adverse reactions." The dose given to our patients, however, corresponds to a massive overdose for which side effects are sporadically reported (respiratory depression and various mental disturbances)."
Respiratory insufficiency was seen in two of our patients, but this could have been due to other causes. Nevertheless, a relation between high dose dextromethorphan and pneumonia cannot be excluded, as we also noted pneumonia in another (unpublished) The decision to initiate treatment with dextromethorphan might have been too late for three of our patients. A future study design should consider an earlier introduction of dextromethorphan in patients with acute neurological diseases and epilepsy. In acute neurological diseases transient antagonism of the NMDA receptor may suffice to prevent brain damage by NMDA receptor mediated excitotoxicity. The blockade of NMDA receptors seems to be necessary until the overflow of excitatory amino acids is reduced or the reuptake system is stabilised. We assume that 10 days of high dose dextromethorphan and stepwise discontinuation over seven days would be an appropriate mode of treatment. Dextromethorphan should be discontinued or reduced before extubation is performed to avoid possible respiratory problems.
Long term administration of dextromethorphan is limited in childhood epilepsies, unless the underlying disease (non-ketotic hyperglycinaemia) requires a continuous NMDA receptor blockade. The supposed involvement of NMDA receptors in learning and memory processes suggests that long term treatment with NMDA antagonists is not desirable, especially in childhood.
As successful treatment with dextromethorphan is also limited by the unreliability of the oral route, intravenous treatment would have preference. Treatment with dextrorphan, the more potent compound at the NMDA receptor, might also overcome individual metabolic differences and improve reliability.
